Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918546 | 0.80 | SYK (0.33) | SYKKCNH2JAK2 | |
| SCHEMBL9920236 | 0.71 | JAK2 (0.48) | JAK2JAK1TYK2 | |
| SCHEMBL9918530 | 0.67 | LRRK2 (0.38) | SYKKCNH2NUDT1JAK2JAK1 | |
| SCHEMBL9918544 | 0.67 | SMN1; SMN2 (0.44) | SYKNUDT1TTBK1TTBK2LRRK2 | |
| SCHEMBL9918526 | 0.65 | LRRK2 (0.43) | SYKKCNH2LRRK2 | |
| SCHEMBL9918521 | 0.65 | IGF1R (0.34) | JAK2JAK1LRRK2 | |
| SCHEMBL12832928 | 0.64 | LRRK2 (0.45) | NUDT1PRKCIJAK2JAK1TYK2 | |
| SCHEMBL12832699 | 0.64 | JAK2 (0.34) | SYKKCNH2JAK2JAK1TYK2 | |
| SCHEMBL9918528 | 0.64 | SYK (0.32) | SYKKCNH2JAK2JAK1BTK | |
| SCHEMBL9918519 | 0.64 | IGF1R (0.33) | SYKKCNH2JAK2JAK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | BRD4 402/4885ROCK2 483/4885SYK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.